Document is current
Any future updates will be listed below
-
Authors
Brück, Oscar https://orcid.org/0000-0002-7842-9419
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 24 November 2023
First Online: 11 December 2023
Competing interests
: O.B. declares no competing non-financial interests but the following competing financial interests: consultancy fees from Novartis, Sanofi, and Amgen, outside the submitted work, and research grants from Pfizer and Gilead Sciences, outside the submitted work.
